Evidence map›Paper›PMID 35476955›Full record

ArticleTransplantation and cellular therapy2022

Outcomes of Refractory Cytomegalovirus Infection in the First Year after Allogeneic Hematopoietic Cell Transplantation.

Eleni Karantoni, Phaedon D Zavras, Yiqi Su, Jiaqi Fang, Roni Tamari, Christina Cho, Miguel-Angel Perales, Anat Stern, Genovefa A Papanicolaou

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation and cellular therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Eleni KarantoniInfectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Phaedon D ZavrasInfectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York; Laboratory of Translational Oncology, Medical School, University of Crete, Greece.
Yiqi SuInfectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Jiaqi FangInfectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Roni TamariAdult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, Cornell University, New York, New York.
Christina ChoAdult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, Cornell University, New York, New York.
Miguel-Angel PeralesAdult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, Cornell University, New York, New York.
Anat SternInfectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Genovefa A PapanicolaouInfectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: papanicg@mskcc.org.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
T LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SCHEINBERG, DAVID A · 1985 to 2023
$59.0M
NCI NIH HHS P01 CA023766NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Outcomes of refractory (Rf) cytomegalovirus (CMV) infection (CMVi) after hematopoietic cell transplantation (HCT) are poor owing to limited treatment options and treatment related toxicities. Maribavir, an orally bioavailable CMV antiviral, was recently approved for treatment of Rf-CMVi. Real-world studies quantifying the burden of Rf-CMVi prior to maribavir provide a benchmark for evaluating the net value of novel treatments. Here we report the incidence, clinical outcomes, and healthcare resource utilization (HRU) associated with Rf-CMVi in the first year post-HCT in a cohort of CMV-seropositive HCT recipients (R+) who underwent HCT between January 1, 2014, and December 31, 2017, at Memorial Sloan Kettering Cancer Center and were managed exclusively by preemptive therapy. CMVi was defined as CMV viremia treated preemptively. Rf-CMVi was defined as a <1 log

Indexed as

Cytomegalovirus InfectionsHematopoietic Stem Cell TransplantationAntiviral AgentsCytomegalovirusHumansTransplant RecipientsViremiaAntiviral AgentsAllogeneic hematopoietic cell transplantationCMV end-organ diseaseCytomegalovirusHealthcare resource utilizationMortalityPreemptive therapyRefractory CMV

Identifiers

PMID35476955
PMCPMC10243123
OpenAlexW4224882648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.